05.18.23 -- Final FDA Guidance Defines Suspect & Illegitimate Drug Product

With a Drug Supply Chain Security Act deadline looming, the FDA published its final guidance clarifying terms the agency uses to describe illegitimate and suspect drug product.

Prior knowledge, platforms, parallel backup programs, and strategic timing all come into play when rapidly scaling up a mAbs development program in response to a public health emergency.